StockData
Century Therapeutics, Inc. logo

Century Therapeutics, Inc. (IPSC) stock

IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$1.38+0.01 (+0.73%)

Close on Nov 18, 2026Market cap $249.88MP/E –Yield –

Century Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Century Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$88.09M. For fiscal 2025 it was -$104.72M. The highest annual figure on record is -$16.55M in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$104.72M–
FY2024Dec 31, 2024-$110.29M–
FY2023Dec 31, 2023-$102.08M–
FY2022Dec 31, 2022-$16.55M–
FY2021Dec 31, 2021-$133.97M–
FY2020Dec 31, 2020-$51.09M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$20.53M–
Q1 FY2026Mar 31, 2026-$25.85M–
Q4 FY2025Dec 31, 2025-$15.94M–
Q3 FY2025Sep 30, 2025-$25.78M–
Q2 FY2025Jun 30, 2025-$27.91M–
Q1 FY2025Mar 31, 2025-$35.10M–
Q2 FY2024Jun 30, 2024-$27.60M–
Q1 FY2024Mar 31, 2024-$30.79M–
Q4 FY2023Dec 31, 2023-$27.21M–
Q3 FY2023Sep 30, 2023-$16.91M–
Q2 FY2023Jun 30, 2023-$23.75M–
Q1 FY2023Mar 31, 2023-$34.21M-141.4%
Q4 FY2022Dec 31, 2022-$29.18M–
Q3 FY2022Sep 30, 2022-$34.05M–
Q2 FY2022Jun 30, 2022-$36.01M–
Q1 FY2022Mar 31, 2022$82.69M–
Q4 FY2021Dec 31, 2021-$41.07M–
Q3 FY2021Sep 30, 2021-$39.72M–
Q2 FY2021Jun 30, 2021-$29.12M–
Q1 FY2021Mar 31, 2021-$24.06M–
Q4 FY2020Dec 31, 2020-$15.12M–
Q3 FY2020Sep 30, 2020-$13.73M–

More Century Therapeutics figures

See a number that looks wrong?